Back to Search
Start Over
Evaluation of Efficacy of Adding Aprepitant to Palonosetron and Dexamethasone in Carboplatin and Etoposide Therapy.
- Source :
-
Biological & pharmaceutical bulletin [Biol Pharm Bull] 2024; Vol. 47 (6), pp. 1189-1195. - Publication Year :
- 2024
-
Abstract
- Although carboplatin (CBDCA) is classified as a moderately emetogenic agent, the majority of guidelines recommend the use of a neurokinin-1 receptor antagonist in addition to a 5-hydroxytryptamine type 3 receptor antagonist with dexamethasone (DEX) for CBDCA-containing chemotherapy because of its higher emetogenic risk. However, the additional efficacy of aprepitant (APR) in CBDCA-containing treatment remains controversial, and data on multiple-day treatments are limited. Etoposide (ETP) was administered on days 1-3 in the CBDCA + ETP regimen, and it is important to evaluate suitable antiemetic therapy for the regimen. Therefore, we evaluated the efficacy of additional APR in CBDCA + ETP. Patients were divided into two groups and retrospectively evaluated. One was the control group, which was prophylactically administered palonosetron (PALO) and DEX, and the other was the APR group, which received APR orally with PALO and DEX. The primary endpoint was complete response (CR) between the groups. The overall CR rates were 75.0 and 76.4% in the control and APR groups, respectively, with no significant difference (p = 1.00). In the acute phase, it was 88.9 and 97.2%, respectively, and 86.1 and 79.2% in the delayed phase, respectively, without significant differences (p = 0.10 and 0.38, respectively). The incidence and severity of nausea, vomiting, and anorexia were not significantly different between the two groups in the acute and delayed phases. Our findings suggest that combining APR with PALO and DEX does not improve the CR rate in CBDCA + ETP therapy.
- Subjects :
- Humans
Male
Female
Middle Aged
Aged
Retrospective Studies
Adult
Drug Therapy, Combination
Antineoplastic Combined Chemotherapy Protocols adverse effects
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Quinuclidines administration & dosage
Quinuclidines therapeutic use
Morpholines administration & dosage
Morpholines therapeutic use
Antineoplastic Agents administration & dosage
Antineoplastic Agents therapeutic use
Antineoplastic Agents adverse effects
Isoquinolines administration & dosage
Isoquinolines therapeutic use
Treatment Outcome
Aprepitant therapeutic use
Aprepitant administration & dosage
Carboplatin administration & dosage
Carboplatin therapeutic use
Carboplatin adverse effects
Dexamethasone administration & dosage
Dexamethasone therapeutic use
Palonosetron administration & dosage
Palonosetron therapeutic use
Etoposide administration & dosage
Etoposide therapeutic use
Antiemetics administration & dosage
Antiemetics therapeutic use
Vomiting chemically induced
Vomiting prevention & control
Nausea chemically induced
Nausea prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 1347-5215
- Volume :
- 47
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Biological & pharmaceutical bulletin
- Publication Type :
- Academic Journal
- Accession number :
- 38897969
- Full Text :
- https://doi.org/10.1248/bpb.b24-00046